MENU
+Compare
EXEL
Stock ticker: NASDAQ
AS OF
Dec 12 closing price
Price
$40.88
Change
-$0.51 (-1.23%)
Capitalization
10.96B

EXEL Exelixis Forecast, Technical & Fundamental Analysis

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer... Show more

Industry: #Biotechnology
EXEL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for EXEL with price predictions
Dec 11, 2025

EXEL's RSI Oscillator leaves overbought zone

The 10-day RSI Indicator for EXEL moved out of overbought territory on November 13, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 instances where the indicator moved out of the overbought zone. In of the 41 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 08, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on EXEL as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for EXEL turned negative on December 08, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXEL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

EXEL broke above its upper Bollinger Band on November 26, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

EXEL moved above its 50-day moving average on November 05, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for EXEL crossed bullishly above the 50-day moving average on November 05, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

The 50-day moving average for EXEL moved above the 200-day moving average on November 07, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EXEL advanced for three days, in of 314 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 278 cases where EXEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EXEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.074) is normal, around the industry mean (28.362). P/E Ratio (17.176) is within average values for comparable stocks, (51.986). Projected Growth (PEG Ratio) (2.618) is also within normal values, averaging (1.836). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (5.112) is also within normal values, averaging (336.196).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
EXEL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

EXEL is expected to report earnings to fall 2.10% to 76 cents per share on February 10

Exelixis EXEL Stock Earnings Reports
Q4'25
Est.
$0.76
Q3'25
Beat
by $0.09
Q2'25
Beat
by $0.11
Q1'25
Beat
by $0.25
Q4'24
Beat
by $0.16
The last earnings report on November 04 showed earnings per share of 77 cents, beating the estimate of 68 cents. With 2.57M shares outstanding, the current market capitalization sits at 10.96B.
A.I. Advisor
published General Information

General Information

a developer of small molecule therapies for the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
1851 Harbor Bay Parkway
Phone
+1 650 837-7000
Employees
1310
Web
https://www.exelixis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BKCG36.430.15
+0.41%
BNY Mellon Concentrated Growth ETF
FDEC50.850.09
+0.18%
FT Vest US Equity Buffer ETF Dec
ARCM100.30N/A
N/A
Arrow Reserve Capital Management ETF
SEPM31.73N/A
N/A
FT Vest U.S. Eq Max Buffr ETF - Sep
TSI4.94-0.01
-0.30%
TCW Strategic Income Fund

EXEL and Stocks

Correlation & Price change

A.I.dvisor tells us that EXEL and TECH have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EXEL and TECH's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
+0.78%
TECH - EXEL
33%
Poorly correlated
-0.94%
MRSN - EXEL
32%
Poorly correlated
+0.43%
ORMP - EXEL
32%
Poorly correlated
+4.66%
AXON - EXEL
31%
Poorly correlated
+2.22%
RVMD - EXEL
28%
Poorly correlated
+0.81%
More